Stem cell manipulation: Why and how performing peripheral blood progenitor cell purging

Critical Reviews in Oncology/Hematology

Volumn 26, Issue 2, 1997, Pages 101-115

  Rizzoli, Vittorio ^a   Carlo Stella, Carmelo ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; CD34 ANTIGEN; GENISTEIN; HERBIMYCIN A; MAFOSFAMIDE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUERCETIN; TYRPHOSTIN;

CELL SELECTION; HEMATOPOIETIC STEM CELL; HUMAN; MINIMAL RESIDUAL DISEASE; NONHUMAN; PERIPHERAL BLOOD STEM CELL; REVIEW; STEM CELL TRANSPLANTATION; TUMOR CELL;

ANIMALS; BONE MARROW PURGING; CELL SEPARATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; NEOPLASM, RESIDUAL; NEOPLASMS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030839842     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)00014-0     Document Type: Review

References (156)

1. Dicke KA, Zander A, Spitzer G, et al. Autologous bone marrow transplantation in relapsed adult acute leukemia. Lancet 1979;I:514-7.
2. Appelbaum FR. Marrow transplantation for hematologic malignanices: a brief review of current status and future prospects. Semin Hematol 1988;25(3):16-22.
3. Advisory Committee of the International Autologous Bone Marrow Transplant Registry. Autologous Bone Marrow Transplant. Different indications in Europe and North America. Lancet 1989;II:317-21.
4. Chopra R, Goldstone AH. Modern trends in bone marrow transplantation for acute myeloid and acute lymphoblastic leukemia. Curr Opin Oncol 1992;4:247-58.
5. Santos GW, Yeager AM, Jones RJ. Autologous bone marrow transplantation. Annu Rev Med 1989;40:99-112.
6. Jones RJ. Autologous bone marrow transplantation. Curr Opin Oncol 1993;5:270-5.
7. Gianni AM. Where do we stand with respect to the use of peripheral blood progenitor cells?. Ann Oncol 1994;5:781-4.
8. Rizzoli V, Carlo-Stella C. Stem cell purging: an intriguing dilemma. Exp Hematol 1955;23:296-302.
9. Crown J, Norton L. Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. Ann Oncol 1995;6(4):S21-6.
10. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-38.
11. Hillyer CD, Wells SJ. Alternative sources of hematopoietic stem cells for bone marrow trasplantation and rescue. J Hematother 1993;2:491-9.
12. Eaves CJ. Peripheral blood stem cells reach new heights. Blood 1993;82:1957-9.
13. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1966;347:353-7.
14. Siena S, Bregni M, Di Nicola M, et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994;5:935-41.
15. + cell sorting system. Bone Marrow Transplant 1996;18:1117-21.
16. Pantel K. Detection of minimal residual disease in patients with solid tumors. J Hematother 1996;5:359-67.
17. Kvalheim G, Wang MY, Pharo A, et al. Purging of tumor cells from leukapheresis products: experimental and clinical aspects. J Hematother 1996;5:427-36.
18. Tavassoli M, Hardy CL. Molecular basis of homing of intravenously transplanted stem cells to the marrow. Blood 1990;76:1059-70.
19. Aurer I, Gale RP. Are new conditioning regimens for transplants in acute myelogenous leukemia better?. Bone Marrow Transplant 1991;7:255-62.
20. Slavin S, Ackerstein A, Naparstek E, et al. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?. Bone Marrow Transplant 1990;6:155-61.
21. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068-73.
22. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
23. Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. Ann Int Med 1986;105:20-6.
24. Barrett AJ, Jiang YZ. Immune response to chronic myelogenous leukemia. Bone Marrow Transplant 1992;9:305-11.
25. Bianco JA, Appelbaum FR. Biotherapy after marrow transplantation and the use of hematopoietic growth factors. Curr Opin Oncol 1990;2:289-96.
26. Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic behaviour of hematopoietic stem cells. Cell 1986;45:917-27.
27. Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev 1990;4:220-32.
28. Gordon MY. Physiological mechanisms in BMT and haemopoiesis - revisited. Bone Marrow Transplant 1993;11:193-7.
29. Scott MA, Gordon MY. In search of the haemopoietic stem cell. Br J Haematol 1995;90:738-43.
30. Carlo-Stella C, Rizzoli V. Stem cells and stem cell factor(s). Haematologica 1995;80:1-4.
31. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature 1989;339:27-30.
32. Orlic D, Bodine DM. What defines a pluripotent hematopoietic stem cell (PHSC): will the real PHSC stand up!. Blood 1994;84:3919-94.
33. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993;81:2844-53.
34. Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994;371:221-6.
35. Sutherland HJ, Eaves CJ, Eaves AJ, et al. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 1989;74:1563-70.
36. Petzer AL, Hogge DE, Lansdorp PM, et al. Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA 1996;93:1470-4.
37. Pantel K, Braun S, Passlick B, et al. Minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. Prog Histochem Cytochem 1996;30:1-69.
38. Shpall EJ, Jones RB. Release of tumor cell from bone marrow. Blood 1994;83:623-5.
39. Ross AM, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay technique. Blood 1993;82:2605-10.
40. Simpson SJ, Vachula M, Kennedy JM, et al. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol 1995;23:1062-8.
41. Ross AA, Loudovaris M, Hazelton B, et al. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients. Exp Hematol 1995;23:1478-83.
42. Hildebrandt M, Mapara MY, Kšrner IJ, et al. Reverse transcriptase-polymerase chain reaction (RT-PCR)-controlled immunomagnetic purging of breast cancer cells using the magnetic cell separation (MACS) system: a sensitive method for monitoring purging efficiency. Exp Hematol 1977;25:57-65.
43. Brugger W, Bross KJ, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636-40.
44. Gordon MY. Adhesive properties of haemopoietic stem cells. Br J Haematol 1988;68:149-52.
45. 4 integrin. Proc Natl Acad Sci USA 1993;90:9374-8.
46. Demirer T, Bensinger WI. Optimization of peripheral blood stem cell collection. Curr Opin Hematol 1995;2:219-26.
47. Gribben JG, Freedman AS, Neuberg D, et al. Imunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525-33.
48. Sharp JC, Kessinger A, Mann S, et al. Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Cloning 1992;10(1):92-4.
49. Cagnoni PJ, Shpall EJ, Bearman SI, et al. High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results. Bone Marrow Transplant 1996;18(1):S26-9.
50. Brenner MK, Rill DR, Holladay MS, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993;342:1134-7.
51. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85-6.
52. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-3.
53. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068-76.
54. Campana D, Coustan-Smith E, Behm FG. The definition of remission in acute leukemia with immunologic techniques. Bone Marrow Transplant 1991;8:429-37.
55. Martens ACM, Schultz FW, Hagenbeck A. Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood 1987;70:1073-8.
56. Hogge DE. Cytogenetics and oncogenes in leukemia. Curr Opin Oncol 1994;6:3-13.
57. Cuneo A, Wlodarska I, Aly MS, et al. Non-radioactive in situ hybridization for the detection of trisomy 12 in B-cell chronic lymphocytic leukaemia. Br J Haematol 1992;81:192-6.
58. Campana D, Coustan-Smith E, Janossy G. The immunologic detection of MRD in acute leukemia. Blood 1990;76:163-71.
59. Negrin RS, Blume KG. The use of the polymerase chain reaction for the detection of minimal residual malignant disease. Blood 1991;78:255-8.
60. Van Dongen JJM, Breit TM, Adriaansen HJ, et al. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992;6(1):47-59.
61. Wormann B. Implications of detection of minimal residual disease. Curr Opin Oncol 1993;5:3-12.
62. + cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 1994;83:1744-8.
63. Estrov Z, Grunberger T, Dubé ID, et al. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained dunng remission. N Engl J Med 1986;315:538-42.
64. Burnett AK. Autologous transplantation in acute leukemias, including purging. Curr Opin Oncol 1990;2:263-8.
65. Gulati SC, Acaba L. Rationale for purging in autologous stem cell transplantation. J Hematotherapy 1993;2:467-71.
66. Santos GW, Colvin MO. Pharmacological purging of bone marrow with reference to autografting. Clin Hematol 1986;15:67-83.
67. Uckun FM, Gajl-Peczalska K, Meyers DE, et al. Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. Blood 1987;69:361-6.
68. Berenson R. Transplantation of hematopoietic stem cells. J Hematotherapy 1993;2:347-9.
69. Hervé P, Tamayo E, Peters A. Autologous stem cell grafting in acute myeloid leukemia: technical approach of marrow incubation in vitro with pharmacological agents (prerequisite for clinical applications). Br J Haematol 1983;53:683-5.
70. Eaves C, Udomsakdi C. Cashman J, et al. Biology of normal and neoplastic stem cells in CML. Leuk Lymph 1993;11(1):245-53.
71. Daley GD, Goldman JM. Autologous transplant for CML revisited. Exp Hematol 1993;21:734-7.
72. Schultz FW, Martens ACM, Hagenbeek A. The contribution of residual leukemic cells in the graft to leukemia relapse after autologous bone marrow transplantation: mathematical considerations. Leukemia 1989;3:530-4.
73. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation intoSCID mice. Nature 1994;367:645-8.
74. Shpall EJ, Gee A, Cagnoni PJ, et al. Stem cell isolation. Curr Opin Hematol 1995;2:452-9.
75. Sharkis SJ, Santos GW, Colvin OM. Elimination of acute myelogenous leukemic cells from marrow and tumor suspension in the rat with 4-hydroperoxycyclophosphamide. Blood 1980;55:521-3.
76. Rowley SD, Colvin M, Stuart RK. Human multilineage progenitor cell sensitivity to 4-hydroperoxycyclophosphamide. Exp Hematol 1985;13:295-8.
77. Douay L, Mary JY, Giarratana MC, et al. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (Asia Z 7557). Exp Hematol 1989;17:429-32.
78. Carlo-Stella C, Mangoni L, Almici C, et al. Differential sensitivity of adherent CFU-Blast, CFU-Mix, BFU-E and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. Exp Hematol 1992;20:328-33.
79. Gorin NC, Acgerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990;75:1606-14.
80. Rizzoli V. Mangoni L, Carlo-Stella C. Autologous bone marrow transplantation in acute myelogenous leukemia. Leukemia 1992;6:1101-6.
81. Bullock G, Tang C, Tourkina E, et al. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp Hematol 1993;21:1640-7.
82. Almici C, Mangoni L, Carlo-Stella C, et al. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow. Bone Marrow Transplant 1995;16:95-101.
83. Ball ED. In vitro purging of bone marrow for autologous marrow transplantation in acute myelogenous leukemia using myeloid-specific monoclonal antibodies. Bone Marrow Transplant 1988;3:387-92.
84. Lšwenberg B, Bauman JGJ. Further results in understanding the subpopulation structure of AML: clonogenic cells and their progeny identified by differentiation markers. Blood 1985;66:1225-32.
85. Griffin JD, Lšwenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986;68:1185-95.
86. Eaves CJ, Cashman JD, Eaves AC. Methodology of long-term culture of human hematopoietic cells. J Tiss Cult Methods 1991;13:55-62.
87. Coulombel L, Kalousek DK, Eaves CJ, et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983;308:1493-8.
88. Testa NG, Dexter MT. The biology af long-term bone marrow cultures and its application to bone marrow transplantation. Curr Opin Oncol 1991;3:272-8.
89. Udomsakdi C, Eaves CJ, Swolin B, et al. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 1992;89:6192-6.
90. Gordon MY, Dowding CR, Riley GP, et al. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987;328:342-4.
91. Carlo-Stella C, Mangoni L, Piovani G, et al. Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. Blood 1994;83:1373-80.
92. Chang J, Morgenstern GR, Coutinho LH, et al. The use of bone marrow cells grown in long-term culture for autologous bone marrow transplantation in acute myeloid leukaemia: an update. Bone Marrow Transplant 1989;4:5-9.
93. Barnett MJ, Eaves CJ, Phillips GL, et al. Successful autografting in chronic myeloid leukemia after maintenance of marrow in culture. Bone Marrow Transplant 1989;4:345-51.
94. Shannon K. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. Curr Opin Hematol 1995;2:305-9.
95. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-8.
96. Levitzki A. Tyrphostins-tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB 1992;J 6:3275-82.
97. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988;319:990-8.
98. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984;37:1035-42.
99. McWhirter JR, Wang JYJ. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr-abl fusion proteins. Mol Cell Biol 1991;11:1553-65.
100. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinase. J Biol Chem 1987;262:5592-5.
101. Hill TD, Dean NM, Mordan LJ, et al. PDGF-induced activation of phospholipase C is not required for induction of DNA sysnthesis. Science 1990;248:1660-3.
102. Kuriu A, Ikeda H, Kanakura Y, et al. Proliferation of human myeloid leukemia cell line associated with the tyrosine phosphorylation and activation of the proto-oncogene c-kit product. Blood 1991;78:2834-40.
103. Traganos F, Ardelt B, Halko N, et al. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 1992;52:6200-8.
104. Okura A, Arakawa H, Oka H, et al. Effect of genistein on topoisomerase activity and on the growth of (Val 12)Ha-ras-transformed NIH cells. Biochem Biophys Res Commun 1988;157:183-9.
105. Honna Y, Okabe-Kado J, Kasaukabe T, et al. Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K-562 cells. Jpn J Cancer Res 1990;81:1132-7.
106. bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood 1992;80:1330-8.
107. Carlo-Stella C, Dotti G, Mangoni L, et al. Selection of myeloid progenitors lacking BCR-ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 1996;88:3091-100.
108. Anafi M, Gazit A, Gilon C, et al. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J Biol Chem 1990;267:4518-23.
109. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
110. Moore MAS. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 1991;78:1-19.
111. Smith C, Gasparetto C, Collins NM, et al. Purification and partial characterization of a human hematopoietic precursor population. Blood 1991;77:1218-27.
112. Carlo-Stella C, Mangoni L, Piovani G, et al. Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. Blood 1994;83:1373-80.
113. Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133:157-65.
114. Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 1989;169:1721-31.
115. Sutherland RD, Keating A. The CD34 antigen: structure, biology and potential clinical applications. J Hematother 1992;1:115-29.
116. Carlo-Stella C, Cazzola M, De Fabritiis P, et al. CD34-positive cells: biology and clinical relevance. Haematologica 1995;80:367-87.
117. Civin CI, Gore SD. Antigenic analysis of hematopoiesis: a review. J Hematother 1993;2:137-44.
118. + hemaopoietic cells from human bone marrow. J Exp Med 1990;172:363-6.
119. Baum CM, Weissman IL, Tsukamoto AS, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992;89:2804-8.
120. - hematopoietic stem cells. Blood 1994;83:1515-26.
121. high cells. Blood 1993;82:3283-9.
122. Rosnet O, Marchetto S, deLapeyriere O, et al. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/ CSF1R family. Oncogene 1991;6:1641-50.
123. Matthews W, Jordan CT, Wiegand GW, et al. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991;65:1143-52.
124. + human bone marrow cells and is involved in the proliferatiob of early progenitor/stem cells. Proc Natl Acad Sci USA 1994;91:459-63.
125. Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993;75:1157-67.
126. Lyman SD, James L, Johnson L, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994;83:2795-801.
127. Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/ FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994;368:643-8.
128. Kmiecik TE, Keller JE, Rosen E, et al. Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood 1992;80:2454-7.
129. Metcalf D. Hematopoietic regulators: redundancy or subtlety?. Blood 1993;82:3515-23.
130. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994;84:1421-6.
131. Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994;12:28-36.
132. + progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. Blood 1995;86:4691-8.
133. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995;86:390-7.
134. Johnson RJ, Owen RG, Smith GM, et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 1996;17:723-7.
135. + myeloma cells. Br J Haematol 1996;93:613-22.
136. + cells to remove circulating tumor cells. Blood 1996;87:1625-34.
137. Muench MO, Firpo MT, Moore MAS. Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 1993;81:3463-9.
138. + cells into the myeloid lineage. Blood 1992;80:1405-12.
139. + progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, I.L-3, interferon-gamma, and erythropoietin. Blood 1993;81:2579-84.
140. +-selected human peripheral blood progenitor cells. Blood 1994;84:2898-903.
141. Verfaillie CM. Can human hematopoietic stem cells be cultured ex vivo?. Stem Cells 1994;12:466-76.
142. Lansdorp PM. Developmental changes in the function of hematopoietic stem cells. Exp Hematol 1995;23:187-91.
143. Simmons PJ, Haylock DN. Use of hematopoietic growth factors for in vitro expansion of precursor cell populations. Curr Opin Hematol 1995;2:189-95.
144. Koller MR, Manchel I, Newsom BS, et al. Bioreactor expansion of human bone marrow: comparison of unprocessed, density-separated, and CD34-enriched cells. J Hematother 1995;4:159-69.
145. + cell selection and perfusion on ex vivo expansion of peripheral blood mononuclear cells. Blood 1995;86:958-70.
146. Williams DA. Ex vivo expansion of hematopoietic stem and progenitor cells - Robbing Peter to pay Paul?. Blood 1993;81:3169-72.
147. Brugger W, Heimfeld S, Berenson RJ, et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995;333:283-7.
148. Alcorn MJ, Holyoake TL, Richmond L, et al. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 1996;14:1839-47.
149. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol 1996;24:859-62.
150. + blood progenitors for anticancer therapy. Exp Hematol 1995;23:1463-71.
151. Fujiwara T, Grimm EA, Roth J. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol 1994;6:96-104.
152. Fruehauf S, Boesen JJ, Breems DA, et al. Retroviral transfer of the multidrug resistance-1 gene into lineage-committed and primitive hemopoietic cells. Stem Cells 1995;13(3):93-9.
153. + selection systems or CAMPATH-1. Exp Hematol 1995;23:147-54.
154. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell depleted haploidentical 'three loci' incompatible transplants in leukemia patients by addition of rhG-CSF mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-55.
155. + blood cells. Blood 1996;87:4903-9.
156. + blood cells additionally T-cell depleted with CAMPATH-1H. Blood 1996;88(1):262b (abstract).